01
Ask
Research question
What evidence supports HER2 as a target for ADC therapies in solid tumors?
02
Collect Evidence
Relevant publications 245 Results
HER2-targeted ADCs in breast and gastric cancer
Novel linker technologies for HER2 ADCs
03
Evaluate
Observe pertinent project information
Evidence summary
Comparing evidence
Contradictory findings
Study limitations
04
Generate Hypotheses
Proposed hypotheses
Next-generation HER2 ADCs with optimized linker chemistry may improve therapeutic window in HER2-low tumors.
Rationale: strong biological basis, supporting preclinical evidence, identified research gaps
05
Output Report
Generated research report
Evidence summary
Hypothesis list
Key uncertainty flags
Recommended next steps